Does Rallies show Form 4 insider transactions for CTMX?

Yes. Rallies tracks CTMX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CTMX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CTMX. It does not provide personalized investment advice.

CTMX (CytomX Therapeutics, Inc.) Stock Analysis - Insider Trades

CytomX Therapeutics, Inc. (CTMX) is a publicly traded Healthcare sector company. As of May 21, 2026, CTMX trades at $3.74 with a market cap of $761.96M and a P/E ratio of 0.00. CTMX moved +2.06% today. Year to date, CTMX is -9.71%; over the trailing twelve months it is +80.58%. Its 52-week range spans $0.40 to $8.21. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces CTMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CTMX stock inside the company?

Recent CTMX insider activity includes Chu Yu-Waye sold 21.28K, McCarthy Sean A. sold 118.97K, BELVIN MARCIA sold 31.49K, Ogden Christopher sold 19.32K, and McCarthy Sean A. sold 101.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CTMX Key Metrics

Key financial metrics for CTMX
Metric	Value
Price	$3.74
Market Cap	$761.96M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$8.21
52-Week Low	$0.40
Volume	20
Avg Volume	0
Revenue (TTM)	$35.54M
Net Income	$-59.14M
Gross Margin	0.00%

Recent CTMX Insider Trades

Chu Yu-Waye sold 21.28K (~$136.68K) on Mar 17, 2026.
McCarthy Sean A. sold 118.97K (~$764.14K) on Mar 17, 2026.
BELVIN MARCIA sold 31.49K (~$202.27K) on Mar 17, 2026.
Ogden Christopher sold 19.32K (~$124.11K) on Mar 17, 2026.
McCarthy Sean A. sold 101.79K (~$461.91K) on Nov 6, 2025.

Latest CTMX News

CytomX Raises $250M, Holds $346.7M Cash; Varseta-M Dose Expansion Completes Enrollment — May 7, 2026
CytomX Therapeutics Prices $250M Offering of 45.99M Shares at $5.30 — Mar 18, 2026
CytomX Initiates $250M Offering as Varseta-M Phase I Shows 32% Response — Mar 17, 2026
CytomX Launches $250M Stock Offering with $37.5M Overallotment Option — Mar 16, 2026
CytomX Targets Multibillion-Dollar Market with Varseta-M Registrational Trial — Mar 16, 2026

CTMX Analyst Consensus

9 analysts cover CTMX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.

Common questions about CTMX

Who is trading CTMX stock inside the company?: Recent CTMX insider activity includes Chu Yu-Waye sold 21.28K, McCarthy Sean A. sold 118.97K, BELVIN MARCIA sold 31.49K, Ogden Christopher sold 19.32K, and McCarthy Sean A. sold 101.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CTMX?: Yes. Rallies tracks CTMX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CTMX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CTMX. It does not provide personalized investment advice.